DIGEST
The digest printed below was prepared by House Legislative Services. It constitutes no part of the
legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law
or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]
HB 813 Reengrossed 2024 Regular Session Edmonston
Abstract: Provides that no healthcare professional licensing board of the state shall prohibit or
restrict the prescribing, administering, or dispensing of drugs for off-label use.
Present law provides for licensure and regulation by the state of various types of healthcare
professionals.
Proposed law retains present law and provides that no healthcare professional licensing board or
commission shall prohibit or restrict the prescribing, administering, or dispensing for an off-label
use of a human drug that has been approved for a specific use by the U.S. Food and Drug
Administration (FDA) during a declared public health emergency.
Proposed law defines "off-label use", for purposes of proposed law, as the use of a prescription drug
for an indication for which it has not been approved by the FDA or the use of such drug in an age
group, dosage, or route of administration that has not been approved by the FDA.
(Adds R.S. 37:1704)
Summary of Amendments Adopted by House
The Committee Amendments Proposed by House Committee on Health and Welfare to the
original bill:
1. Remove the La. Dept. of Health from the list of entities prohibited from making rules
limiting off-label use of drugs approved by the FDA.
The House Floor Amendments to the engrossed bill:
1. Add that a board or commission may not prohibit prescribing, administering, or
dispensing a drug for a human that was approved by the FDA during a declared public
health emergency.